Business Wire Feed
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT
Bracco's new BubbleGen technology streamlines cell therapy manufacturing for one-step cell separation and activation with no magnetic residuals BubbleGen microbubbles can target specific cell subtypes, including rare populations Demos available for BubbleGen at ISCT, Booth more...
New Pharmaceutical Reform Alliance Poll: Americans Agree on One Thing – Rein in Big Pharma
WASHINGTON--(BUSINESS WIRE)--Today, the Pharmaceutical Reform Alliance (PRA) released new national polling results that show significant consensus across party lines that affordability is a top concern for voters, especially regarding healthcare and prescription drugs costs. As more...
NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD
New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily more...
Hepta Reveals Blood-Based Epigenetic Signatures of GLP-1 Response, Enabling Precision Medicine in Obesity and MASH
New data from the SAMARA trial mark the first known demonstration that a blood test can identify semaglutide weight-loss responders before treatment begins and track drug effects over timeFOSTER CITY, Calif.--(BUSINESS WIRE)--GLP-1 medicines are being more...
GC Therapeutics Appoints Stem Cell Therapy Leader Stefan Irion, MD, as Chief Scientific Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome™ (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) programming platform that enables expansion into in vivo rejuvenation and more...
Pediatrica Health Group Acquires Miami Practice, Expanding and Enhancing Equitable Access to Care as Population Growth Soars
Company Supports Westchester Provider to Continue a Legacy of Outstanding Care and Community LeadershipMIAMI--(BUSINESS WIRE)--Miami-based Pediatrica Health Group, a multi-site pediatric primary care organization that is setting a new standard in pediatric care delivery and more...
Most Workers Say Menopause Shouldn’t Be Ignored at Work
New Wondr Health / Harris Poll data signals strong expectations for employer support across women’s healthDALLAS--(BUSINESS WIRE)--Workplace expectations around women’s health are shifting, and menopause remains an overlooked area for employer support. A national survey more...
Patients at Vierra Falls Church Gain Access to Expert Cardiac Care with Arrival of Dr. Walid Alami
FALLS CHURCH, Va.--(BUSINESS WIRE)--#CardiacCare--Vierra Falls Church Health & Rehab is pleased to announce that Dr. Walid Alami, MD, FACC, FSCAI, a renowned board-certified interventional cardiologist, has joined its clinical team, marking a significant expansion of more...
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Blood-based test enables identification of patients eligible for targeted treatment with VEPPANU™ Approval marks Guardant’s third ESR1 companion diagnostic FDA approval to help guide timely treatment decisions for patients with advanced breast cancer PALO ALTO, more...
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7 million patient treatment-resistant depression market — — Phase 2b Ongoing with topline more...
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
- Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=<0.0001) reduction in primary endpoint of cholestatic pruritus - Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) scheduled for more...
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
Increased All-Cash Tender Offer Price of $21.80 per share – or $153.2 Million New Tender Offer Price Represents 21.1% Premium to Prior OfferLAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today more...
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial restoration of more...
Rejoni Appoints Women’s Health MedTech Leader John Nealon as Chief Executive Officer
BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company based in Bedford, MA, dedicated to elevating uterine health through innovative biomaterial therapies, today announced the appointment of John Nealon as Chief Executive Officer. A seasoned more...
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial more...
Newly Published Study Shows Sensome Clot-Sensing Guidewire Accurately Reveals True Clot Make-Up in Fully Occluded Brain Vessels for First Time
In Situ Clot Intelligence Designed to Address Imaging Blind Spots During Mechanical ThrombectomyPARIS--(BUSINESS WIRE)--#cardiology--Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced the publication of first-in-human results from its CLOT OUT more...
Karlie Kloss Joins Board of Miami’s Lotus Endowment Fund and Pledges $1 Million to Support Children’s Village at the Nation’s Largest Women’s Shelter
Kloss’ addition to the board of Lotus Endowment Fund, Inc., the supporting foundation for Lotus House, will advance the nonprofit’s mission to end and prevent homelessness. The gift will sponsor the Children’s Village complimentary Clothing more...
NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite
The first consumer experiences powered by true molecular medicine infrastructure are now live at lite.dendrite.com. Take a quiz built from your own genome. Read the seven-chapter story of your biology. Then bring your family.SALT LAKE more...
ŌURA Closes the Hormonal Health Data Gap
First-of-its-kind Hormonal Birth Control experience and proprietary Menopause Insights translate complex hormonal shifts into clear, personalized guidance across every life stageSAN FRANCISCO--(BUSINESS WIRE)--ŌURA, maker of the world’s leading smart ring, today announced two new experiences more...
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association more...
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi XR will be available for pharmacy orders by May more...
Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange. The more...
Mettler-Toledo International Inc. Announces Webcast of Presentation at the BofA Securities 2026 Healthcare Conference
COLUMBUS, Ohio--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE:MTD) today announced it will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026, at 8:00 a.m. (PT). A live webcast of the presentation will be more...
Myomo to Report First Quarter 2026 Financial Results on May 7
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report more...
PACS Group Announces Acquisition in Alaska; New Construction of a Skilled Nursing Community
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) today announced that independently operated subsidiaries of the Company have acquired the operations of the post-acute care facility Ridgeway Senior Living in Anchorage, more...